FDA Oncology Announcements

Anti-BCMA CAR T-cell × Clear all

2 Announcements

FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma

Trial: CARTITUDE-1
Drug: CARVYKTI (ciltacabtagene autoleucel) · Anti-BCMA CAR T-cell
Condition: Plasma cell

FDA approves idecabtagene vicleucel for multiple myeloma

Trial: KarMMa
Drug: Abecma (idecabtagene vicleucel) · Anti-BCMA CAR T-cell
Condition: Plasma cell